Freeline Therapeutics Holdings plc (NASDAQ:FRLN) has seen 1.98 million shares traded in the last trading session. The company, currently valued at $70.90M, closed the last trade at $1.73 per share which meant it lost -$0.25 on the day or -12.63% during that session. The FRLN stock price is -968.79% off its 52-week high price of $18.49 and -10.4% below the 52-week low of $1.91. If we look at the company’s 10-day average daily trading volume, we find that it stood at 4.88 million shares traded. The 3-month trading volume is 819.45K shares.
The consensus among analysts is that Freeline Therapeutics Holdings plc (FRLN) is a Buy stock at the moment, with a recommendation rating of 1.80. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 7 have rated it as a Hold, with 7 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.73.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Sporting -12.63% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Friday, 01/07/22 when the FRLN stock price touched $1.73 or saw a rise of 34.22%. Year-to-date, Freeline Therapeutics Holdings plc shares have moved -12.63%, while the 5-day performance has seen it change -12.63%. Over the past 30 days, the shares of Freeline Therapeutics Holdings plc (NASDAQ:FRLN) have changed -31.89%. Short interest in the company has seen 46360.0 shares shorted with days to cover at 0.37.
Wall Street analysts have a consensus price target for the stock at $12.57, which means that the shares’ value could jump 86.24% from current levels. The projected low price target is $9.00 while the price target rests at a high of $20.00. In that case, then, we find that the current price level is -1056.07% off the targeted high while a plunge would see the stock gain -420.23% from current levels.
Freeline Therapeutics Holdings plc (FRLN) estimates and forecasts
Figures show that Freeline Therapeutics Holdings plc shares have outperformed across the wider relevant industry. The company’s shares have lost -78.74% over the past 6 months, with this year growth rate of 47.72%, compared to 7.80% for the industry. Other than that, the company has, however, increased its growth outlook for the 2022 fiscal year revenue. Growth estimates for the current quarter are 17.00% and 33.70% for the next quarter.
Freeline Therapeutics Holdings plc is expected to release its next earnings report on November 09 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Freeline Therapeutics Holdings plc (NASDAQ:FRLN)’s Major holders
Insiders own 8.24% of the company shares, while shares held by institutions stand at 30.18% with a share float percentage of 32.89%. Investors are also buoyed by the number of investors in a company, with Freeline Therapeutics Holdings plc having a total of 22 institutions that hold shares in the company. The top two institutional holders are Eventide Asset Management LLC with over 3.49 million shares worth more than $11.89 million. As of Sep 29, 2021, Eventide Asset Management LLC held 9.73% of shares outstanding.
The other major institutional holder is Novo Holdings A/S, with the holding of over 1.93 million shares as of Sep 29, 2021. The firm’s total holdings are worth over $6.58 million and represent 5.38% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Harbor Disruptive Innovation Fund. As of Sep 29, 2021, the former fund manager holds about 6.30% shares in the company for having 2.26 million shares of worth $7.7 million while later fund manager owns 0.19 million shares of worth $0.57 million as of Oct 30, 2021, which makes it owner of about 0.54% of company’s outstanding stock.